MicroRNA-155 Is Required for Effector CD8+ T Cell Responses to Virus Infection and Cancer

Jan C. Dudda, Bruno Salaun, Yun Ji, +16

Immunity

Virus InfectionImmunologyCd4 T Cell ResponsesSmall RnaCellular Immune Response +6

Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity

Rachel Perret, Sophie Sierro, Natalia K. Botelho, +3

Cancer Research

Combination of lentivector immunization and low‐dose chemotherapy or PD‐1/PD‐L1 blocking primes self‐reactive T cells and induces anti‐tumor immunity

Sophie Sierro, Alena Donda, Rachel Perret, +4

European Journal of Immunology

Programmed DeathImmunologyCd4 T Cell ResponsesImmunotherapeuticsT Cells +18

Effector lymphoid tissue and its crucial role in protective immunity

Rachel Perret, Marianne N. Prout, Franca Ronchese

Trends in Immunology

InflammationAutoimmune DiseaseLymphocyte DevelopmentImmune RegulationImmunology +9

Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response

Matthew Peacey, Sarah Wilson, Rachel Perret, +5

Vaccine

Anti-tumor ResponseViral PathogenesisAntiviral ResponsePathologyVirology +4

CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses

Stéphanie Corgnac, Rachel Perret, Laurent Derré, +7

Cancer Immunology Immunotherapy

Dendritic Cells Treated with Lipopolysaccharide Up-Regulate Serine Protease Inhibitor 6 and Remain Sensitive to Killing by Cytotoxic T Lymphocytes In Vivo

Kate A. Andrew, Helen Mary Alys Simkins, Sabine Witzel, +6

The Journal of Immunology

Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines

Nathaly Castro-Díaz, Bruno Salaun, Rachel Perret, +5

Vaccine

VaccinationVaccine DevelopmentVaccine ResearchDefense SystemsMedicine +7

iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine

Stéphanie Corgnac, Rachel Perret, Lianjun Zhang, +3

Journal for ImmunoTherapy of Cancer

Effector CD8⁺ T cells activated <i>in vitro</i> confer immediate and long‐term tumor protection <i>in vivo</i>

Rachel Perret, Franca Ronchese

European Journal of Immunology

Tumor ProtectionImmunologyImmunoeditingCd4 T Cell ResponsesT Cells +14